ArticleCell reports. Medicine2022
Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV.
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Mucosal leishmaniasis of the lips and cheeks: a first concomitant presentation of visceral and mucosal leishmaniasis in a patient living with HIV/AIDS in Monastir, Tunisia.AIDS research and therapy · 2024Pooled it
- Systemic inflammatory markers of visceral leishmaniasis treatment response in East Africa.PLoS neglected tropical diseases · 2026Article
- From dogma to data: charting a path forward for clinico-immunological research in Ethiopian cutaneous leishmaniasis.Infectious diseases of poverty · 2026Review
- [Temporal trends and clinical-epidemiological profile of visceral leishmaniasis-HIV coinfection in Brazilian states between 2009 and 2024].Cadernos de saude publica · 2026Article
- Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review.BMJ public health · 2026Article
- mNGS-Assisted Diagnosis of Visceral Leishmaniasis Presenting as Hemophagocytic Lymphohistiocytosis: Two Cases Confirmed by rK39.Infection and drug resistance · 2026Article
- Persistent myeloid cell reprogramming despite miltefosine treatment in leishmania-infected macaques.iScience · 2025Article
- The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.Parasites & vectors · 2025Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Cytokine Production in Response to Soluble Leishmania Aethiopica Antigen by Whole Blood Cells from Patients with Different Clinical Presentations of Cutaneous Leishmaniasis.The American journal of tropical medicine and hygiene · 2025Article
- An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025Review
- Assessment of asymptomaticFrontiers in medicine · 2025Article
- Insights to the HIV-associated visceral leishmaniasis clinical outcome: lessons learned about immune mediated disorders.Frontiers in immunology · 2025Review
- Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study.EBioMedicine · 2024Article
- Altered co-stimulatory and inhibitory receptors on monocyte subsets in patients with visceral leishmaniasis.PLoS neglected tropical diseases · 2024Article
- An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection.PLoS neglected tropical diseases · 2024Article
- Low Plasma Lipids Are Associated with Relapsing and Lethal Visceral Leishmaniasis in HIV-Infected Patients.Pathogens (Basel, Switzerland) · 2024Article
- Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients.Communications biology · 2024Article
- The spleen is the graveyard of CD4+ cells in patients with immunological failure of visceral leishmaniasis and AIDS.Parasites & vectors · 2024Article
- Immune response to viscerotropicFrontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Visceral leishmaniasis (VL) has emerged as a clinically important opportunistic infection in HIV patients, as VL/HIV co-infected patients suffer from frequent VL relapse. Here, we follow cohorts of VL patients with or without HIV in Ethiopia. By the end of the study, 78.1% of VL/HIV-but none of the VL patients-experience VL relapse. Despite a clinically defined cure, VL/HIV patients maintain higher parasite loads, lower BMI, hepatosplenomegaly, and pancytopenia. We identify three immunological markers associated with VL relapse in VL/HIV patients: (1) failure to restore antigen-specific production of IFN-γ, (2) persistently lower CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.